

Date: June 14, 2017

То	То
Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sirs,

Sub: Presentation to the Investors / Analysts.

We would like to inform you that the Company is participating in Goldman Sachs Healthcare conference on 14 June 2017 in USA starting at 10.30 am of US time. The attached presentation will be used in the conference.

The presentation is also being uploaded on the website of the Company -

http://www.aurobindo.com/investor-relations/investors/investor-presentation

Please take the information on record.

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

B.Re.

B.Adi Reddy Company Secretary



(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No. 11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059 Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com





LEADING VERTICALLY INTEGRATED GENERIC PLAYER

Goldman Sachs Healthcare Conference June 2017





This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any part hereof, form the basis of, or be relied on in connection with, any contract therefore.

This presentation contains statements that constitute "forward looking statements" including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance.

While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, regulatory and legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance.

Aurobindo Pharma undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances.

This document is strictly confidential and may not be disclosed, reproduced or redistributed, in whole or in part, to any other person.

For updates and specific queries, please visit our website www.aurobindo.com

- Among the Top-3 listed pharmaceutical companies from India by sales⁽¹⁾
 - 6th largest generic company by volume in the US⁽²⁾; IMS TRx represents greater than 28% growth year over year ⁽³⁾
 - Broad portfolio of diversified dosage forms including Rx and OTC oral solids, liquids, injectables, and ophthalmics
- One of the highest rates of vertical integration, incorporating in-house API in 70% of total formulations
- Global presence, with critical mass in US and EU markets
- Well entrenched US portfolio of 429⁽⁴⁾ filed ANDAs with 276⁽⁴⁾ final approvals
- Diversified manufacturing footprint spread across multiple regions and sites, offering extended capability and capacity








Emerged into a leading global generic player





The Journey So Far...



2006-08

- Acquired UK based Milpharm
- Acquired formulations facility in US
- Investment in building manufacturing, marketing & IPR capabilities

2010-12

- Commenced operations of Unit VII and Aurolife facilities
- First Controlled Substance product approved in US
- Entered into Peptide business

2006 - 2012

Formulation Focus + Establishing Global Footprint

2013

- Commenced marketing specialty injectables in USA
- Building capabilities in Penem and Oncology

2014

- Acquired Western European commercial operations from Actavis
- Acquired Natrol

2015-17

- Focus on differentiated technology platforms
- Entered into Biosimilars and Vaccines

2013-2017

Consolidating Presence in US & EU + Expanding Injectables & Differentiated Offerings

1992-2006

- Commencement of export of APIs
- Initial Public Offering ('95)
- Entered into formulation business ('02)

Pre-2006

API Focus



Scale & Leadership

- Large manufacturing facilities inspected by leading regulatory bodies
- Well diversified product portfolio
- Large, World-class R&D Centers for formulations and active pharmaceutical ingredients
- Significant presence in the US and EU (~45% and ~22% of revenue in FY17)

Operational Strengths


- High vertical integration
- Robust and highly scalable formulations
- Extensive product pipeline (~153 ANDAs pending final approval*)
- Capability and capacity for large volumes
- Diversity of dosage forms

Customer Centricity

- Global marketing network in over 150 countries
- Customer centric approach and relationship oriented marketing
- Speed and effectiveness in execution

Diversified Revenue Base & Strong Organic growth







Financial Performance



Operating income (US\$ Mn)




EBITDA & PAT Margin (%)







EPS (INR/Share)




Gross Block & Fixed Asset Turnover



Average ROE & ROCE %



Net Debt/Eq & Net Debt/EBITDA




Gross Block is calculated as Tangible Assets + Intangible Assets-Goodwill

* As per Indian Accounting Standards (Ind AS), **includes sales from limited competition product


Our Business Segments





*Source: IMS National Prescription Audit, Total Prescriptions Dispensed, Twelve months ending April 2017 **Source: Market Reports, ***as on 31 Mar 2017


US Business Overview



US: Expanding Portfolio Mix Towards Differentiated Products

Unit wise ANDA Filings as on 31-March-2017

Site	Details	Final Approval	Tentative Approval	Under Review	Total
Unit III	Oral Formulations	100	16	10	126
Unit IV	Injectables & Ophthalmics	41	2	35	78
Unit VIB	Cephalosphorins Oral	11			11
Unit VII (SEZ)	Oral Formulations	88	20	50	158
Unit X	Oral Formulations			4	4
Unit XII	Penicillin Oral & Injectables	19		1	20
Aurolife USA	Oral Formulations	16		10	26
AuroNext	Penem Injectables	1		3	4
Eugia	Oral & Injectable Formulations			2	2
Total		276	38	115	429



Growth Drivers in the next 3-4 years

- Broadening portfolio with more balance through accelerated growth in injectable, OTC, and higher complexity products
- Increasing collaboration across the global customer base
- Operational efficiencies and cost leadership in API and formulation manufacturing, supply chain planning and distribution

Enhanced Research & Development Capabilities

5 R&D centers in Hyderabad, India

- Focused on difficult to develop API, niche oral, sterile and specialty injectable
- Concentrating on wide range of Oncology, Hormonal products, Penems, Enzymes, Biocatalysts, vaccines and Peptides
- Developing diverse pipeline of biosimilars in Oncology and Immunology. CHO-GS based cell lines with productivity of ~ 4.0 g/L
- In the preventive healthcare area, working on various OTC and Dietary Supplement products
- Dedicated solid state characterization lab involving powder characterization capabilities
- New chemical technology has been adopted to improve the productivity and efficiency of the existing processes
- Two of the R&D centres has been audited by USFDA

1 R&D center in Dayton, New Jersey


- Developing microsphere technology based specialty injectable products
- Concentrating on development of various niche oral formulation and controlled substances
- Focus on developing tamper/abuse-resistant technology based products

1 R&D center in Raleigh, North Carolina

- Developing various respiratory and nasal products, including MDIs
- Dermal Delivery portfolio including transdermal and topical products

Highly qualified and experienced team of >1,400 professionals

Focus on building differentiated product portfolio



Significant investment in research initiatives (new labs, experienced scientists)

Future pipeline will include Oncology Products, Hormones, Depot injections, Peptides, Inhalers, Patches, Films, Vaccines, Biosimilars and Differentiated Oral delivery Products




EU Business Overview

									\square	
France Germany	Netherlands	Spain	UK	Ро	rtugal	Italy	Ro	omania	Belgiu	Im
 India's Leading Gx compa > Operations in 9 countri > Significant presence at Germany > Commercialized over 4 Presence across Gx, TG2 and hospital sales infrasti Successful Day 1 launche Voriconazole, Valgancicle Pipeline of over 200 prod 	es with full fledged sa nd position in Top 5 El 450 INNs across 9 cou k, BGx and Hx segmer ructure es of Imatinib, Olmesa ovir, Linezolid in key m	les force & sup U markets led Intries of opera Ints with establi Intan, Olmesard	by France & ation ished commerc			S Revenue 54% CAGR i 8 1 8 1 8 1 1 FY13 FY EU Reve	2 5 3 1 1 14 F	- FY17 26 22 523 479 Y15 FY16* % of Total	22 489 FY17* Revenue	30 25 20 15 10 5 0
 Growth Drivers in the next 3-4 Consolidate presence & i 		ig Top 10 play	ers in each mar	ket						
 Acquisition of Generis Fa by value and volume in th 	• •	U 1	to the # 1 posi	tion				p 5 EU countr	ries	
 Completed acquisition of branded products portfolio Drug Market 	Orocal brand; to bolst	er Arrow's con	•		Country	Mark size (l Bn	JS\$	APL Presence	APL's positior	า
 Expanding into new geog 	raphies viz. Poland ar	nd Czech Repu	ublic		Germany			✓ ✓	8 th	
 Portfolio Expansion throu 	•	•		ems,	UK	24		1	11 th	
Oncology Products, Niche				- ,	Italy	29		1	10 th	
 Lower generics penetration potential as share of generation 	• •	•	offer future gro	wth	France Spain	33 21		✓ ✓	6 th 9 th	

EU: Portfolio Mix Across Channels






Channels	Gx	BGx	Hx	TGx
Geographies	All 9 countries	7 countries	All 9 countries	Germany, Spain & Netherlands
# of Products	769 (primarily tablets & capsules)	34	347 (predominantly injectables)	767 (including Gx products)
Other Highlights	Amongst top 10 in most significant markets	Includes leading brands such as Neotigason, Floxapen, Bezalip among others	Focus on high value areas including oncology	Tender based business

ARV Business Overview

- Focus on global tenders floated by Multi-Lateral Organizations like Global Fund, USAID/PEPFAR and Country specific MOH tenders; currently caters to 2.2 million HIV+ patients
- Well integrated supply chain management services and logistics for ARV supplies (29 products) catering to over 100 countries
- Filed over 1,100 ARV dossiers for registrations across the globe

Growth Driver in the next 3-4 years – Dolutegravir (DTG)

- Aurobindo is the first generic company to sign license with ViiV Healthcare for the next generation Integrase Inhibitor – DTG
 - Received the USFDA approval for DTG 50mg under the PEPFAR program
 - WHO announced this drug as a 1st line reserve drug in its 2015 HIV treatment guidelines
 - Play a collaborative role in upgrading millions of patients to the latest "best-in-class" ARV drug
- Filed an ANDA application for a Triple drug combination containing DTG
- Market size is expected to be US\$ 500 Mn in 2018 for DTG and combinations @50% conversion*




Products
Efavirenz + Lamivudine + Tenofovir
Zidovudine + Lamivudine + Nevirapine Tabs
Lopinavir + Ritonavir Tabs
Lamivudine + Zidovudine Tabs
Abacavir Sulfate Tabs
Efavirenz + Emtricitabine + Tenofovir Tabs
Lamivudine Tabs

^{**}As per Indian Accounting Standards (Ind AS)

^{*}Source: as per HSBC market report

Growth Markets Business Overview






*As per Indian Accounting Standards (Ind AS)

The Base Business : API




- API business continue to focus on high value, specialty, small/midsize products with a limited competition
- Ensures quality & reliability of supplies and ability to command cost efficiencies as well as economies of scale
- Focus on continuous improvement of manufacturing process to meet cost and environmental challenges
- Continue to have sustained growth in more advanced regulated markets (EU, Japan & USA)
- API facilities meet advanced market requirements like USFDA, UK MHRA, EU, Japan PMDA, Mexico COFEPRIS, Brazil-ANVISA, Korea FDA etc.
- Manufacturing reaction volumes has been increased over 30% in last 3 years and would further grow in same proportions.
- Additional processing capacities / capabilities would be created in Oncology and allied areas.
- Conventional manufacturing process are migrated into environmentally friendly process and products based on green chemistry.

Strong Regulatory Capability*




Significant increase in reaction volumes



Debt Profile



Fx Loan US\$ Mn



- Other Term Loans (Subsidiaries) & Unsecured Loans
- ECB APL
- Working Capital

Initiatives to Support Sustainable Future Growth



Short Term

Focus on strengthening the Portfolio, Capability and Capacity as Growth Drivers

New facilities and distribution center

- 3 manufacturing facilities in Naidupet, Vizag and Jedcherla, all in India.
- New automated distribution center in the US
- Tripling production capacity of US facility

R&D centers

- Increase controlled substance filings to at least 7 per year for future growth
- Fully operational R&D center in North Carolina; filings in inhalation and topical therapies

Peptides

 4 DMF filings in FY17. Plans to file upto 15 DMFs. Commercial supplies to increase considerably

<u>ARV</u>

Full impact of Dolutegravir and its combination

Oncology and Hormones

• File around 30+ products

<u>отс</u>

Strengthening the US OTC portfolio

US Branded Products Portfolio

 Build a portfolio of 505b2 products in select therapeutic areas and initiate development work

Medium Term

Commercial Drivers: Focus on launches

Peptides

Additional product launches

Oncology and Hormones

- 20+ more products to be filed
- Product launches and commercialization starts from April '19

Microspheres (Depot Injections)

 All 4 products which are under development will be filed and commercialization begins

<u>Inhalers</u>

- Development work to commence for 4 more products in addition to 2 products
- First set of product launches and commercialization starts

Vaccines

 2019 - Commercial launch of Bx of pneumococcal conjugate vaccine with an addressable market size of US\$ 6 Bn.

Increased Filing for Sustainable Future Growth

Biosimilars

- Commence of manufacturing facility
- Start filing Biosimilars globally
- Commercialization to begin for Emerging Markets from FY20

US Branded Products - Filing

- Filing 1-2 505b2 NDAs per year
- Accelerate in-licensing differentiated products and technologies
- Diversify the portfolio target specific patient population to meet unmet medical needs

Long Term

Focus on increasing and sustaining the number of filings and launches of high-value products

<u>Inhalers</u>

Focus on product launches

Vaccines

• Strengthen the portfolio

Biosimilars

 Commercialization to begin for Advanced markets

Branded Products - Launches

- Launch 1-2 branded product per year
- · Secure exclusivity

Branded Products - Filings

• Increase the number filings

OTC Brands

• Target 2-3 launches per year

Thank You



For updates and specific queries, please visit our website <u>www. aurobindo.com</u>

Investor Relations: Phone: +91-40-66725401 +91 98486 67906

Email: ir@aurobindo.com

Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084

Registered Office: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500038